Key Points:

• Swiss dental technology company vVardis Holding plans to raise $214 million through an offering of 9.5 million shares priced between $21 and $24 each.
• The proposed IPO implies a market capitalization of approximately $1.3 billion at the midpoint of the range, with the company targeting a listing on the New York Stock Exchange under the ticker VVVV.
• Founded in 2020, vVardis generated $50 million in revenue for the 12 months ended June 30, 2026, with its Curodont cavity-treatment products accounting for its core business.

Swiss dental technology company vVardis Holding has announced terms for a US initial public offering targeting approximately $214 million in gross proceeds. The Zug-based company plans to offer 9.5 million shares at a price range of $21 to $24, potentially establishing a market valuation of approximately $1.3 billion at the midpoint. The proposed listing would give public-market investors exposure to a specialized dental-care business built around non-invasive treatments for early-stage cavities.

Company Background: A Non-Invasive Approach to Cavity Treatment

Founded in 2020, vVardis develops and commercializes Curodont, a proprietary peptide-based treatment designed to address early-stage cavities without conventional drilling or needles. The product is applied in a dental office in five minutes or less, positioning the company within the preventive and minimally invasive segment of dental care.

Its US product, Curodont Repair Fluoride Plus, is marketed as an over-the-counter drug under an FDA monograph and generates the vast majority of the company’s revenue. A fluoride-free version, Curodont Repair, is sold as a medical device in the United Kingdom and parts of Europe. In the United States, vVardis distributes its products exclusively through Henry Schein, supported by its own sales force. The company reported $50 million in revenue for the 12 months ended June 30, 2026, providing an initial measure of its commercial scale ahead of the market debut.

IPO Details: $214 Million Offering and NYSE Listing

vVardis plans to raise approximately $214 million by offering 9.5 million shares at an expected price range of $21 to $24. At the midpoint of $22.50, the proposed transaction implies a market capitalization of approximately $1.3 billion. The company intends to list on the New York Stock Exchange under the ticker symbol VVVV.

Goldman Sachs, J.P. Morgan, William Blair, UBS Investment Bank and Deutsche Bank are serving as joint bookrunners. The offering is expected to price during the week of November 9, 2026. Final pricing, proceeds and valuation will depend on the terms established at the completion of the offering.

Market Opportunity and Investor Considerations

The investment case rests on vVardis’s ability to commercialize a differentiated treatment within a large, established dental-care market. Its non-invasive approach may appeal to dental professionals and patients seeking alternatives to conventional cavity procedures, while its existing US distribution relationship provides an established commercial channel. Revenue of $50 million also demonstrates that the business has moved beyond an early-stage product-development model.

Nevertheless, investors will need to assess the durability of demand, the company’s dependence on its leading US product and its reliance on Henry Schein for US distribution. Regulatory requirements across different markets, competition from established dental-care providers and alternative treatments, and the company’s ability to expand adoption will remain important considerations. The available IPO announcement does not provide profitability figures, so revenue alone cannot establish the company’s earnings profile.

Market Debut Will Test the Strength of Its Commercial Model

vVardis enters the US IPO market with a defined product portfolio, established distribution arrangements and a reported revenue base. Its proposed $1.3 billion valuation will place attention on whether investors believe the company’s treatment platform can support sustained commercial expansion. The market debut may attract interest in the dental technology segment, but the longer-term investment case will depend on revenue growth, operating performance and the company’s ability to broaden adoption beyond its current core product.